Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
Markus Pfirrmann(Ludwig-Maximilians-Universität München), Bengt Simonsson(Uppsala University Hospital), Francisco Cervantes(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Fausto Castagnetti(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Michele Baccarani(University of Bologna), Rüdiger Hehlmann(Heidelberg University), Joerg Hasford(Ludwig-Maximilians-Universität München), Verena Hoffmann(Zimmer Biomet (Germany)), G.J. Ossenkoppele(Amsterdam UMC Location Vrije Universiteit Amsterdam), Joëlle Guilhot(Inserm), Susanne Saußele(University of Mannheim)
Cited by 298
Related Papers
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573